24 July 2015
A new drug has been shown to boost the effectiveness of chemotherapy when treating pancreatic and lung cancers - both of which are very resistant to current treatment methods, and have a high chance of recurring.
A team at the Institute of Cancer Research in London have discovered that in laboratory tests, the substance known as CCT245737 has the ability to cut off cancer’s ways of escaping from chemotherapy by blocking CHK1 molecules in a way not previously observed.
The combination of drugs did not create any additional toxicity throughout the tests, which is a key factor in limiting the unpleasant side effects of chemotherapy. Thanks to these successful results, the technique will now be able to proceed to in-human trials.
Ian Collins, professor of medicinal chemistry at the Institute of Cancer Research, said: "By using CHK1 inhibitors with chemotherapy, we block one of cancer's escape routes and prevent tumours from evading the effects of treatment."
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.